IN8bio, Inc.
INAB
$1.75
-$0.03-1.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.90M | 10.76M | 11.58M | 12.64M | 13.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 330.00K |
| Total Operating Expenses | 21.05M | 23.13M | 26.61M | 29.60M | 31.30M |
| Operating Income | -21.05M | -23.13M | -26.61M | -29.60M | -31.30M |
| Income Before Tax | -20.66M | -23.89M | -27.43M | -30.44M | -31.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.66 | -23.89 | -27.43 | -30.44 | -31.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.66M | -23.89M | -27.43M | -30.44M | -31.88M |
| EBIT | -21.05M | -23.13M | -26.61M | -29.60M | -31.30M |
| EBITDA | -19.16M | -21.12M | -24.73M | -27.76M | -29.50M |
| EPS Basic | -6.48 | -10.12 | -14.39 | -18.33 | -22.51 |
| Normalized Basic EPS | -4.05 | -5.90 | -8.57 | -11.03 | -13.65 |
| EPS Diluted | -6.48 | -10.12 | -14.39 | -18.33 | -22.51 |
| Normalized Diluted EPS | -4.05 | -5.90 | -8.57 | -11.03 | -13.65 |
| Average Basic Shares Outstanding | 14.01M | 11.05M | 8.50M | 7.16M | 5.74M |
| Average Diluted Shares Outstanding | 14.01M | 11.05M | 8.50M | 7.16M | 5.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |